Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy

Investigative Radiology

Volumn 31, Issue 6, 1996, Pages 345-352

  Choe, Bo Young ^a   Suh, Tae Suk ^a   Shinn, Kyung Sub ^a   Lee, Chang Wook ^a   Lee, Chul ^a   Paik, I N H O ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

hydrogen magnetic resonance spectroscopy; Schizophrenia

Indexed keywords

4 AMINOBUTYRIC ACID; CLOZAPINE; CREATINE; CREATINE PHOSPHATE; GLUTAMIC ACID; HALOPERIDOL; INOSITOL; LACTIC ACID; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; PIMOZIDE; PROTON; TRIFLUOPERAZINE;

ADOLESCENT; ADULT; ARTICLE; BRAIN METABOLISM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLITE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RATING SCALE; SCHIZOPHRENIA;

EID: 0029882536     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-199606000-00006     Document Type: Article

References (44)

1. Andreasen NC, Arndt S, Swayze II V, et al. Thalamic abnormalities in schizophrenia visualized through magnetic resonance image averaging. Science 1994;2666:294-297.
2. Africa B, Schwartz SR. Schizophrenia disorders. In: Goldman HH, ed. Review of general psychiatry. 3rd ed. London: Prentice-Hall International Inc., 1992.
3. Carlson NR. Foundations of physiological psychology. 2nd ed. Needam Heights, MA: Allyn and Bacon, division of Simon & Schuster, Inc., 1992.
4. Crow TJ. The continuum of psychosis and its implication for the structure of the gene. Br J Psychiatry 1985;149:419.
5. Andreasen NC, Olsen SA. Negative vs positive schizophrenia: Definition and validation. Arch Gen Psychiatry 1982;39:789-794.
6. Carpenter WT, Kirkpatric B. The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 1988;14:645.
7. Andreasen NC. Brain imaging: Applications in psychiatry. Science 1988;239:1381-1388.
8. Andreasen NC, Nasrallah HA, Dunn V, et al. Structural abnormalities in the frontal system in schizophrenia: A magnetic resonance imaging study. Arch Gen Psychiatry 1986;43:136-144.
9. Breier A, Buchanan RW, Elkashef A, Munson RC, Kirkpatric B, Gellad F. Brain morphology and schizophrenia: A magnetic resonance imaging study of limbic, prefrontal cortex, and caudate structures. Arch Gen Psychiatry 1992;49:921-926.
10. Lieberman J, Bogerts B, Degreef G, Ashtari M, Lantos G, Alvir J. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am J Psychiatry 1992;149:784-794.
11. Weinberger DR. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987;44: 660-669.
12. Shenton ME, Kikinis R, Jolesz FA, et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia: A quantitative magnetic resonance imaging study. N Engl J Med 1992;327:604-612.
13. Lieberman J, Bogerts B, Degreef G, Ashtari M, Lantos G, Alvir J. Qualitative assessment of brain morphology in acute and chronic schizophrenia. Am J Psychiatry 1992;149:784-794.
14. DeLisi LE, Stritzke P, Riordan H, et al. The timing of brain morphological changes in schizophrenia and their relationship to clinical outcome. Biol Psychiatry 1992;31:241-254.
15. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med 1990;322:789-794.
16. Carlsson A. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1988;1:179-203.
17. Buchsbaum MS, Ingvar DH, Kessler R, et al. Cerebral glucography with positron emission tomography. Arch Gen Psychiatry 1982;39:251-259.
18. Buchsbaum MS, Nuechterlein KH, Haier RJ, et al. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br J Psychiatry 1990;156:216-227.
19. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J. Negative symptoms and hypofrontality in chronic schizophrenia. Arch Gen Psychiatry 1992;49:959-965.
20. Lock T, Abou-Saleh MT, Edwards RHT. Psychiatry and the new magnetic resonance era. Br J Psychiatry 1990;157:38-55.
21. Keshavan MS, Karpur S, Pettegrew JW. Magnetic resonance spectroscopy in psychiatry: Potential, pitfalls, and promise. Am J Psychiatry 1991;148:976-985.
22. Dager SR, Steen RG. Applications of magnetic resonance spectroscopy to the investigation of neuropsychiatrie disorders. Neuropsychopharmacology 1992;6:249-266.
23. Bottomley PA. Human in vivo NMR spectroscopy in diagnostic medicine: Clinical tool or research probe? Radiology 1989;170: 1-15.
24. Lenkinski RE. Clinical MR spectroscopy. In: Kressel HY, Modic MT, Murphy WA, eds. Syllabus, special course: MR 1990. Chicago, IL: Radiological Society of North America, Inc., 1990.
25. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol 1994;1:211-216.
26. Daly PF, Cohen JS. Magnetic resonance spectroscopy of tumors and potential in vivo clinical applications: A review. Cancer Res 1989;49:770-779.
27. Gur RE, Resnick SM, Gur RC. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: Relationship to symptom specificity. Psychiatry Res 1989;27:325-334.
28. Overall JW, Gorham DR. The brief psychiatric rating scale. Psychiatric Res 1962;10:795-812.
29. Endicott J, Spitzer RL. A diagnostic interview: The schedule for affective disorders and schizophrenia. Arch Gen Psychiatry 1978;35:837-844.
30. American Psychiatric Association, Committee on Nomenclature and Statistics. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987.
31. Spitzer RL, Endicott J, Robins E. Research diagnostic criteria (RDC) for a selected group of function disorders. 3rd ed. New York, NY: New York State Psychiatric Institute, 1978.
32. Kay SR, Opler LA, Lindenmayer JP. Reliability and validity of the positive and negative syndrome scale for schizophrenics. Psychiatry Res 1988;23:99-110.
33. Aue WP. Localization methods for in vivo nuclear magnetic resonance spectroscopy. Magn Reson Med 1986;1:21-72.
34. Ordidge RJ, Bendall MR, Gordon RE, Connelly A. Volume selection for in vivo spectroscopy. In: Govil G, Khetrapal CL, Sarans A, eds. Magnetic resonance in biology and medicine. New Delhi, NY: Tata-McGraw-Hill, 1985:387-397.
35. Frahm J, Merbold KD, Hanicke W. Localized proton spectroscopy using stimulated echoes. J Magn Reson 1987;72:502-508.
36. 1H NMR spectroscopy in patients with chronic hepatic encephalopathy: Analysis of change in cerebral glutamine, choline, and inositols. NMR in Biomed 1991;4:109-116.
37. Frahm J, Bruhn H, Gyngell ML, Merboldt KD, Hanicke W, Sauter R. Localized high-resolution proton NMR spectroscopy using stimulated echoes: Initial applications to human brain in vivo. Magn Reson Med 1989;9:79-93.
38. Petroff OAC, Spencer DD, Alger JR, Prichard JW. High-field proton magnetic resonance spectroscopy of human cerebrum obtained during surgery for epilepsy. Neurology 1989;39:1197-1202.
39. Ross B, Kreis R, Ernst T. Clinical tools for the 90s: Magnetic resonance spectroscopy and metabolic imaging. Eur J Radiology 1992;14:128-140.
40. 1H MRS measurements of GABA in human brain. In: Book of Abstracts: Society of Magnetic Resonance in Medicine 1993. Berkeley, CA: Society of Magnetic Resonance in Medicine, 1993.
41. Tasman A, Goldfinger SM. American Psychiatric Press review of psychiatry. Vol. 10. Washington, DC: American Psychiatric Press, 1991.
42. Kruk ZL, Pycock CJ. Neurotransmitters and drugs. 3rd ed. London: Chapman & Hall, 1991.
43. Zukin S, Javitt DC. The brain NMDA receptor, psychotomimetic drug effects, and schizophrenia. In: Tasman A, Goldfinger SM, eds. Review of Psychiatry. Vol 10. Washington, DC: American Psychiatric Press, 1991.
44. Diehl LW. Schizophrenic syndromes in epilepsies. Psychopathology 1989;22:65-140.